European Patent Appeals Board Rules for Transkaryotic

Law360, New York (October 12, 2003, 12:00 AM EDT) -- A European patent appeals board invalidated a patent that Serono SA claimed had been infringed by Transkaryotic Therapies, Transkaryotic said in a statement.

Serono filed a lawsuit against Transkaryotic in the District Court at The Hague in the Netherlands in February, alleging that Transkaryotic infringed a gene-activation patent related to its drug Replagal for Fabry disease, a rare genetic disorder.

However, the Technical Board of Appeals of the European Patent Office invalidated the patent held by Serono's subsidiary, Applied Research Systems ARS Holdings, N.V., Transkaryotic said...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.